On June 28, the Biden Administration announced a three-part strategy to combat increasing cases of monkeypox in the United States. First, the administration is deploying vaccines from the Strategic National Stockpile, giving priority to areas with high case counts and population risk. Second, the CDC has increased access to testing by shipping additional tests to major commercial laboratories in the U.S. The FDA has also authorized laboratories to use automation and additional testing reagents to increase lab capacity for labs using CDC’s tests. Lastly, the administration has increased communication and collaboration with healthcare providers, public health workers, and community groups to increase awareness of the virus, reduce stigma in at-risk communities, and promote education about transmission and prevention in at-risk communities.